Stony Lonesome Group

About The Fund

Stony Lonesome Group, operating under the website name Dynamk Capital, is a venture capital fund that specializes in expansion, management buyouts/leveraged buyouts (MBO/LBO), and acquisitions. With headquarters at 30 Wall Street, 12th Floor, in New York, New York, Stony Lonesome Group focuses on driving growth in several key industries: FinTech, Financial Services, HealthTech, Fitness, Aerospace, and Defense. They are particularly noted for their expertise in equity investments. Stony Lonesome Group dedicates their resources to the advancement of their portfolio companies by providing not only financial support but also strategic advisory services to assist these businesses in scaling operations, entering new markets, and achieving significant return on investments. Their approach is crafted to capitalize on dynamic market trends and disruptive technologies that can provide competitive advantages within their sectors of interest. By fostering a network of industry experts and utilizing their specialized knowledge, they are well-positioned to identify promising opportunities and guide companies at various stages of development to success. Among the website content for Dynamk Capital, they emphasize their commitment to 'Funding the Future of Life Sciences.' Their site highlights news articulating their portfolio companies' achievements, such as Virica Biotech building an ecosystem to ramp up AAV production, Lucid Scientific's recognition by Memorial Sloan Kettering Cancer Center, and the selection of Virica Biotech as a Lead Project for NIIMBL's biomanufacturing projects. In the biomedical space, Dynamk Capital is involved with investments in companies like Bit.bio, Curibio, and RoosterBio, illustrating their dedication to contributing to advances in medical research and therapies. The website also offers a newsletter subscription service to keep stakeholders informed about news and updates related to Dynamk Capital's activities and insights into the life sciences field.